Published: 18 November 2021
Author(s): Stefano De Servi, Antonio Landi
Issue: March 2022

Procedural myocardial infarction (MI) is among the components of major endpoints of several trials evaluating the effects of different treatment strategies, intracoronary devices and/or drugs in patients with coronary artery disease. To retain the validity of these investigations, definitions of procedural MI need to be soundly linked to outcome data, mostly subsequent mortality (1). The relationship between myocardial damage after percutaneous coronary interventions (PCI) and risk of subsequent mortality is dependent on the amount of the myonecrosis, that is by the infarct size (2,3).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.